Neurology Contract Research Organization Market Set to Surpass USD 14.2 Billion by 2032, Driven by Advances in Neuroscience and Outsourced Clinical Trials

The global Neurology Contract Research Organization (CRO) market has been witnessing remarkable growth, driven by the increasing demand for cost-effective research services in neuroscience and the rising incidence of neurological disorders worldwide. In 2021, the market stood at US$ 7 billion, and is projected to double to US$ 14.2 billion by 2032, growing at a CAGR of 6.7%. Neurology CROs play a crucial role in facilitating clinical research for pharmaceutical, biotech, and medical device companies, helping them navigate complex regulatory environments, conduct specialized clinical trials, and expedite time-to-market for innovative therapies targeting the central nervous system.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33149

The clinical services segment emerged as the market leader, accounting for a substantial share of 31.6% in 2021, thanks to the escalating number of clinical trials across various regions. Meanwhile, the North American region, particularly the United States, dominates the global market due to a high prevalence of neurological disorders, strong healthcare infrastructure, and the presence of major CROs like IQVIA Inc., Charles River Laboratories, and Parexel International. The country's proactive approach to outsourcing and its large patient pool make it a focal point for neurology-related research and development.

✦ Key Highlights from the Neurology CRO Market Report

✦ The market is expected to grow at a CAGR of 6.7% between 2022 and 2032.
✦ Clinical services dominate the market, holding 31.6% of the revenue share in 2021.
✦ Neurology-focused studies contributed 51.3% to the overall market in 2021.
✦ Pharmaceutical and biopharmaceutical companies held a 31.6% market share by end-user.
✦ The U.S. accounted for over 80% of the North American market in 2021.
✦ China emerged as the top market in Asia, holding 18.4% of the global market in 2021.

Market Segmentation Analysis

The neurology contract research organization market is segmented based on service type, study type, and end user. Among services, clinical services lead the way, as they form the backbone of neurology trials including site selection, monitoring, patient recruitment, and trial management. Data management services also form a significant portion of the market, capturing an 18.6% share due to the increasing complexity of neurology trials and the vast datasets generated.

When it comes to study type, neurology-focused trials represent the bulk, holding over 51% of market share. This is driven by the rising prevalence of neurodegenerative diseases like Parkinson's, Alzheimer's, and multiple sclerosis. End users primarily include pharmaceutical and biopharmaceutical companies, which held a commanding 31.6% share in 2021. These players increasingly outsource neurology research due to growing R&D costs, regulatory complexities, and the need to focus on core competencies.

Regional Insights
North America:
North America, especially the U.S., is the largest market for neurology CROs, driven by its robust research ecosystem and growing neurological patient pool. The U.S. alone contributes to 80.9% of the regional market. The presence of major CROs and an aging population prone to neurological disorders contribute significantly to market expansion.

Europe:
In Europe, the U.K. is a major contributor, accounting for 22.9% of the regional market. A strong tradition of outsourcing, coupled with increased private equity investments in CROs, has made the U.K. a favorable ground for neurology research services. Mergers and acquisitions are also shaping the landscape, further strengthening the region's capabilities.

Asia-Pacific:
China is emerging as a powerful contender, holding 18.4% of the global market in 2021. Multinational pharma companies are increasingly shutting down their in-house R&D facilities in China and shifting towards outsourcing models. Local CROs such as Pharmaron Beijing Co., Ltd. are witnessing rapid growth, offering affordable yet high-quality services in neurology.

Market Drivers

The surge in neurological disorders, such as Alzheimer's, Parkinson's, and epilepsy, is a significant driver. As per the Parkinson's Prevalence Project, the U.S. alone could have 1.2 million Parkinson's patients by 2030. With over 11,000 neurology trials active globally, the demand for CROs specializing in neurology has intensified. Furthermore, the cost-saving potential of outsourcing, combined with access to experienced regulatory professionals and advanced trial infrastructure, fuels the reliance on neurology CROs. Outsourcing also allows pharmaceutical firms to streamline internal resources while benefiting from the operational and therapeutic expertise of CROs.

Market Restraints

One major hurdle for the neurology CRO market is the shortage of highly skilled professionals, especially those with specialization in neuroscience. With CROs competing for top talent with large pharmaceutical and research institutions, attracting and retaining such professionals is a challenge. This talent gap can affect the quality, consistency, and reliability of outsourced trials. Additionally, varying global regulations and stringent compliance frameworks can make execution complex and resource-intensive.

Market Opportunities

Significant opportunities lie in digital transformation and decentralized clinical trials (DCTs). The integration of AI, real-world data, wearable technology, and remote monitoring is streamlining data collection and improving patient recruitment. Emerging markets like India, Brazil, and South Korea also present untapped potential due to increasing healthcare investment and favorable government policies supporting clinical research outsourcing. Moreover, neurological drug pipelines are expanding, creating consistent demand for specialized CRO services to bring these treatments to market faster.

Reasons to Buy the Report

✔ Gain deep insights into current and projected market trends up to 2032.
✔ Understand the impact of neurological disorders on CRO market growth.
✔ Access detailed segmentation based on services, study types, and end users.
✔ Identify regional opportunities across North America, Europe, and Asia-Pacific.
✔ Get competitive intelligence on major players and recent strategic developments.

Company Insights

• IQVIA Inc.
• Charles River Laboratories
• Parexel International Corporation
• Syneos Health
• MD Biosciences
• LabCorp (Covance)
• Medpace Holdings, Inc.
• ICON plc
• Pharmaron Beijing Co., Ltd.
• Novotech

Recent Developments:

In January 2020, Charles River partnered with Takeda Pharmaceutical to accelerate neuroscience and rare disease drug discovery through preclinical candidate development.
In June 2021, MD Biosciences launched a 20,000-square-foot CNS-focused research center in Israel, enhancing its capabilities in neurological studies and drug testing.

Conclusion

The Neurology Contract Research Organization Market is at the forefront of reshaping how neurological treatments are researched, tested, and brought to market. With a growing burden of neurological diseases and the rising cost and complexity of drug development, outsourcing to CROs has become an attractive and strategic solution for many pharmaceutical and biotechnology companies. Supported by digital innovations, global expansion of clinical trials, and evolving regulatory landscapes, neurology CROs are not only helping accelerate time-to-market for life-saving drugs but also improving the economics and success rates of clinical research. As the industry marches toward US$ 14.2 billion by 2032, opportunities abound for innovation, collaboration, and impactful breakthroughs in neuroscience.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.